[SPRINT study: far lower systolic blood pressure]

Area of Science:

• Cardiology
• Hypertension Management
• Clinical Trials

Background:

• No consensus exists on optimal systolic blood pressure targets for reducing cardiovascular events and mortality.
• Previous research, like the ACCORD study, showed no benefit of intensive systolic blood pressure treatment (below 120 mmHg) in diabetic patients.

Purpose of the Study:

• To evaluate the impact of intensive systolic blood pressure lowering on cardiovascular outcomes and mortality.
• To compare intensive treatment (below 120 mmHg) versus standard treatment (below 140 mmHg) for systolic hypertension.

Main Methods:

• The ACCORD study compared intensive versus standard systolic blood pressure treatment in individuals with diabetes mellitus.
• The SPRINT study investigated intensive blood pressure lowering (below 120 mmHg) against standard treatment.

Main Results:

• The ACCORD study found no significant influence of intensive treatment on the primary goal in diabetic individuals.
• The SPRINT study demonstrated a favorable effect of intensive blood pressure lowering on a combined primary endpoint including myocardial infarction, stroke, heart failure, and cardiovascular death.
• Intensive treatment in the SPRINT study also led to a statistically significant increase in adverse events such as hypotension, syncope, and renal injury.

Conclusions:

• Intensive systolic blood pressure lowering may offer benefits in reducing cardiovascular events for certain populations, as suggested by the SPRINT study.
• However, intensive treatment is associated with a higher risk of adverse events, necessitating careful patient selection and monitoring.
• Further research is needed to establish definitive consensus on optimal blood pressure targets for diverse patient groups.